Navigation Links
PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
Date:12/19/2007

Trial designed to evaluate effectiveness of RenalGuard(TM) in preventing

Contrast -Induced Nephropathy

FRANKLIN, Mass., Dec. 19 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC), a company focused on innovative cardiac and vascular medical device-based technologies, announced today that it has named two lead investigators for the upcoming pivotal trial of its RenalGuard Therapy(TM). The lead investigators are Charles Davidson, MD, Professor of Medicine, Northwestern University Medical School and Richard J. Solomon, MD, Professor of Medicine, University of Vermont College of Medicine. The trial is designed as a multi-center, prospective, randomized controlled trial to evaluate the effect of RenalGuard(TM) in the prevention of Contrast-Induced Nephropathy (CIN) during cardiovascular and peripheral imaging procedures performed in a catheterization lab. PLC intends to begin enrollment in the RenalGuard Pivotal Trial in early 2008, following receipt of the necessary approval from the U.S. Food & Drug Administration.

"Contrast-Induced Nephropathy is the third most common cause of in- hospital acute renal failure," stated Dr. Solomon. "The data on current prevention methods is largely inconclusive. It is our hope that this study will help determine the preventative benefits of RenalGuard Therapy in clinical use."

Dr. Davidson added, "CIN is a major issue for at-risk patients undergoing imaging procedures and can result in longer hospital stays and higher mortality rates. A cost-effective, easy-to-use preventive measure could reduce costs and save lives."

RenalGuard is an investigational system and therapy that targets patients with compromised renal function who may be at risk for CIN. Renal
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a ... it has entered into new agreements covering its supply ... the kidney care division of DaVita Healthcare Partners Inc. ... the use of products for home hemodialysis in ... a second amended and restated National Service Provider Agreement ...
(Date:5/21/2013)... 2013   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Operating Officer and Executive Vice President, Finance, will present ... Healthcare Conference on Wednesday, May 29, 2013 at 3:30 ... Westin Boston Waterfront Hotel. The presentation will ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 /PRNewswire/ ... new corporate image and impressive new product developments at the ... . "After ten years of unerring focus on product literature ... the need to mark the occasion," said founding director ... have some interesting developments of benefit to our clients and ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
... CHICAGO, Oct. 28 The non-profit Midwest Business Group ... with numerous local and national organizations, have launched a health ... personal contact to help people improve and manage health conditions. ... ) information series will run through the end of ...
... 28 Amira Pharmaceuticals, Inc. announced today that it ... a novel LPA1 antagonist, in normal, healthy subjects. ... exploring the therapeutic value of AM152, a potentially novel ... safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this ...
Cached Medicine Technology:New 'Take Control of Your Health' Education Series to Improve Health of Chicagoans 2Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2
(Date:5/21/2013)... Paris, France: One-year results from SOURCE XT one ... registries to-date reported today at EuroPCR 2013 show ... rates of device success for all access approaches, valve ... Study followed up 2688 consecutively enrolled patients (mean age ... valve at 93 centres in 17 countries between July ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... cuts readmissions , , WEDNESDAY, May 6 (HealthDay News) -- ... airway pressure (CPAP) may help improve outcomes in patients ... CPAP is commonly used to treat sleep apnea. ... Chest , included 232 cardiac surgery patients who ...
... Former McKesson executive to lead further innovation of ... government agencies and wellness companiesBEDFORD, Mass., May 6 ... management software solutions, today announced that Bill Wisotzkey ... and design, effective immediately. Wisotzkey has more than ...
... outbreak in Mexico, the Foreign and Commonwealth Office (FCO) is advising against ... it will consider all claims for cancelled holidays to the country, scheduled ... ... (PRWEB) -- In the wake of the swine flu outbreak in Mexico, ...
... PHILADELPHIA, May 6 The Mobile Massage Team ( ... services for corporate wellness programs, promotional events, and special affairs, ... exhibitor at the 3rd Annual GlobalFit Worksite Wellness Summit ( ... 14, 2009 at The Down Town Club in Center City ...
... conference focused on promoting physical activity on college ... on connecting health care providers and the public ... infiltrating college campuses nationwide. The American College of ... On Campus," a program component to address and ...
... Against Tobacco Recognized Nationally--WASHINGTON, May 6 ... named Youth Advocates of the Year by the Campaign ... fight against tobacco. Members of REAL are being honored ... the nation,s capital tonight (May 6) along with a ...
Cached Medicine News:Health News:Casenet Names Bill Wisotzkey Vice President of Product Management and Design 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 3Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 2Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 3Health News:Campaign for Tobacco-Free Kids Honors REAL of Hawai'i As Youth Advocates of the Year 2
Jayle tying forceps, straight....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Medicine Products: